metaEvidence - overview


			deaths (OS)
mBC - TNBC - L1 - PDL1 positive breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab plus SoC vs. placebo plus SoC	2	0.82 [0.70; 0.95], 2 RCTs, I2=0% conclusive high degree of certainty